Eli Lilly told CNBC the company is committed to doing its part to give patients reasonable access to the treatments they need, but added there's no easy answer to lowering the price of drugs.

"A permanent solution that gives everyone who uses insulin reasonable access will require leadership and cooperation across many stakeholders, including manufacturers, PBMs, payers, and policymakers," the company said.

Eli Lilly also noted that while the list price for Humalog has gone up, the company receives a lower average net price now than it did in 2009. The company said its third-quarter earnings report on October 25 showed the insulin's U.S. revenue fell 14 percent, driven by a 24 percent decline in net price.